TY - JOUR
T1 - Checkpoint inhibition and cellular immunotherapy in Lymphoma
AU - Lulla, Premal
AU - Heslop, Helen E.
N1 - Funding Information:
This work was supported by a SPORE in Lymphoma grant, a Leukemia and Lymphoma Society SCOR (grant 7018-04), and grants from the National Cancer Institute, National Institutes of Health (grants P50 CA126752 and PO1 CA094237) (H.E.H.) and (grant P50 CA126752) and an ASBMT New Investigator Award (PL.).
PY - 2016
Y1 - 2016
N2 - Hodgkin and non-Hodgkin lymphoma are both good targets for immunotherapy, as they are accessible to antibodies and cell-based immunotherapy, express costimulatory molecules, and express lineage-restricted, viral, and unique tumor antigens. Blockade of the programmed-death 1 (PD-1) immune checkpoint has produced very encouraging response rates in patients with Hodgkin lymphoma, whereas adoptive transfer of Epstein-Barr Virus (EBV)-specific T cells has shown clinical activity in patients with posttransplant lymphoma and other EBV-associated lymphomas. T cells can also be genetically modified with chimeric antigen receptors (CARs) to confer specificity for surface antigens, and studies of CD19 CARs in lymphoma also have had encouraging response rates. Future directions include combination of checkpoint blockade and adoptive T-cell studies.
AB - Hodgkin and non-Hodgkin lymphoma are both good targets for immunotherapy, as they are accessible to antibodies and cell-based immunotherapy, express costimulatory molecules, and express lineage-restricted, viral, and unique tumor antigens. Blockade of the programmed-death 1 (PD-1) immune checkpoint has produced very encouraging response rates in patients with Hodgkin lymphoma, whereas adoptive transfer of Epstein-Barr Virus (EBV)-specific T cells has shown clinical activity in patients with posttransplant lymphoma and other EBV-associated lymphomas. T cells can also be genetically modified with chimeric antigen receptors (CARs) to confer specificity for surface antigens, and studies of CD19 CARs in lymphoma also have had encouraging response rates. Future directions include combination of checkpoint blockade and adoptive T-cell studies.
UR - http://www.scopus.com/inward/record.url?scp=85020312395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020312395&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2016.1.390
DO - 10.1182/asheducation-2016.1.390
M3 - Article
C2 - 27913506
AN - SCOPUS:85020312395
SN - 1520-4391
VL - 2016
SP - 390
EP - 396
JO - Hematology
JF - Hematology
IS - 1
ER -